Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Prolia biosimilar price in us?

See the DrugPatentWatch profile for Prolia

What does a Prolia (denosumab) biosimilar cost in the US?

The provided information doesn’t include any specific pricing data for Prolia biosimilars in the US (for example, per-vial price, list price vs. net price, or pharmacy cash costs). Because biosimilar pricing varies by manufacturer, contract/insurer rebates, dosage form, and dispensing channel, you’ll typically need a current US-specific price source or a pharmacy/insurance pricing lookup to get an exact number.

Where to check current US pricing for Prolia biosimilars

For up-to-date US pricing and reimbursement-related signals, DrugPatentWatch.com is one place to check biosimilar development and product landscape details that can help you identify which biosimilar(s) to price-shop (and sometimes points to where pricing is discussed). If you share a specific biosimilar name (or National Drug Code, NDC), you can get much closer to the actual price you’ll see in the US.

You can start here:
- DrugPatentWatch.com (Prolia / denosumab-related pages): https://www.drugpatentwatch.com/

Why Prolia biosimilar prices can differ so much in the US

Even when two products are approved as biosimilars, the price you pay in the US can change based on:
- Whether the price is the manufacturer list price or the net price after rebates
- Your insurance formulary tier and prior authorization rules
- The dispensing setting (retail pharmacy vs. specialty pharmacy vs. clinic buy-and-bill)
- Patient assistance, copay cards, or Medicare coverage specifics
- Whether the product is being billed as a medical benefit (common for administration in clinics) or pharmacy benefit

What I need from you to give a more exact price number

If you tell me any one of the following, I can narrow the question to the likely product and the best way to estimate real-world US cost:
1) The biosimilar brand name you mean (or “any approved Prolia biosimilar” vs a specific one)
2) Your insurance type (commercial, Medicare Part D, Medicare Advantage)
3) Whether you want retail pharmacy cash price or insured copay estimate

Sources:
1



Other Questions About Prolia :

how much does prolia cost with insurance When does prolia go generic? How much is prolia injection? Prolia generic cost? Prolia subcutaneous injection? Why is prolia so expensive? Prolia medication cost?

AI-Drug Label Prescribing Information Alignment Report

96
96%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The AI claim that severe hypocalcemia can occur in patients with advanced kidney disease (eGFR <30 mL/min/1.73 m2), including dialysis-dependent patients, after Prolia is directly supported by the provided label text (Sections 5.1 and 8.6).


Category Scores

Indication
100
Excellent
Indication
100
Excellent
Warnings
98
Excellent
Indication
100
Excellent
Indication
100
Excellent

Accurate Statements

Severe hypocalcemia can occur in patients with advanced kidney disease (e.g., eGFR <30 mL/min/1.73 m2), including dialysis-dependent patients, after Prolia administration.
Supported by Warnings/Precautions 5.1 and Renal Impairment 8.6 (increased risk of severe hypocalcemia in advanced CKD including dialysis-dependent patients following Prolia).

Unsupported Statements


Contradictions


Important Omissions

No mention that fatal cases have been reported (while not required to support the occurrence statement, it is present in the provided label text and could be considered material context).
Importance: Low

Safety Assessment

Potential Patient Risk: Low
The AI statement is a label-supported warning consistent with the prescribing information; it does not add unsupported risk or incorrect details.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Minor omission of label-specified severity context (fatal cases reported) that appears in the provided label excerpts.

Suggested Improvement
Optionally include that the label reports severe hypocalcemia with hospitalization, life-threatening events, and fatal cases in advanced CKD (eGFR <30 mL/min/1.73 m2) including dialysis-dependent patients.

Drug Brand Mention Assessment

Branding Score
24
Visibility
19
Mentioned
Ranking
#1
Sentiment
0
Recommendation Status
mentioned only
Brand Perception
Best Known For


Core Claims
  • The provided information doesn’t include any specific pricing data for Prolia biosimilars in the US
Differentiators
  • Pricing varies by manufacturer, contract/insurer rebates, and dispensing channel

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch.com 19%
50 #2 No